Vitro Diagnostics (VODG) 0.1000 $VODG
Vitro Biopharma Expands Capacity to Meet Increased Demand for MSC-Gro(TM) Stem Cell Culture Media
ACCESSWIRE - Wed Apr 29, 8:26AM CDT
GOLDEN, CO / ACCESSWIRE / April 29, 2015 / Vitro Diagnostics, Inc. (PINKSHEETS: VODG), dba Vitro Biopharma, announced expansion of manufacturing capacity based on a recent orders for bulk quantities of its MSC-Gro(TM) Brand of stem cell growth media. Increased demand comes from sales to stem cell researchers and a new customer who recently qualified our media for use in its clinical testing program. We have received our initial bulk order based on extensive evaluation of Vitro Biopharma's clinical grade MSC-Gro(TM). The evaluation focused on safety/efficacy parameters and showed safety in animal studies and efficacy through MSC authentication including achievement of phenotypic and functional standards following expansion of human adipose-derived MSCs in MSC-Gro(TM). The function of MSC-Gro(TM) in cell expansion was extensively examined and showed that MSC-Gro(TM) produced superior cellular yields than previously utilized products. Vitro Biopharma anticipates regular orders at levels requiring expanded manufacturing capacity since this customer is known to consume large quantities of media.
AMGN: 162.36 (+0.38)
Vitro Biopharma Announces Advances in Clinical Application of Stem Cell Therapy for Neurological Conditions
ACCESSWIRE - Wed Feb 18, 11:43AM CST
GOLDEN, CO / ACCESSWIRE / February 18, 2015 / Vitro Diagnostics, Inc. (OTCQB:VODG), DBA Vitro Biopharma, announced advances in its stem cell products and services that enhance opportunities to expand clinical studies of stem therapy of neurological conditions. We have previously announced a pre-clinical study of our human MSCs for treatment of stroke in animals that showed near reversal of cell death responses to ischemic stroke by carotid artery occlusion. Recently, the renowned hockey legend, Gordy Howe received a stem cell transplant to treat a prior stroke that left him partially paralyzed, unable to speak and losing weight and quality of life quickly. Shortly following stem cell transplantation in two stages, neural stem cells (NSCs) followed by mesenchymal stem cells (MSCs), he began to walk and talk. At present, he is preparing to attend a hockey gala as a keynote speaker. While his progress is considered outstanding by his family and attending physicians, others criticize this study as uncontrolled. We have recently published a blog summarizing clinical and pre-clinical studies that support further, more extensive clinical trials of stem cell therapy of stroke.
Alternatives to Stem Cell Transplants Supported by Key Medical Breakthroughs of 2014
ACCESSWIRE - Tue Jan 13, 9:18AM CST
GOLDEN, CO / ACCESSWIRE / January 13, 2015 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the growing scientific support for use of stem cells that reside within the body for therapeutic and performance enhancement. A key medical advance of 2014 was research published by scientists at Stanford University and Harvard University regarding mechanisms underlying "parabiosis", the well-known reversal of aging when young animal blood is transferred into older animals. This research, considered a key scientific advance of 2014, identified factors in blood that transform stem cells from an inactive, latent form to active cells that regenerate and replenish aging cells resulting in reversal of aging in animals. This newly identified factor, called growth-differentiation factor 11 (GDF11, or, BMP-11) adds to a growing list of endogenous biological agents that activate stem cells from quiescence to growth and differentiation. The well-known growth factors erythropoietin and G-CSF have been used as therapeutic agents for 25 years to treat anemia and immuno-suppression resulting from chemotherapy. Many stem cells exist within the body in a latent, inactive form ready to be activated by the proper molecular "switch".
Vitro Biopharma Announces CEO Letter to Shareholders: 2014 Revenue Growth Supports 2015 Expansion of Stem Cell Clinical Trials & Revenue
ACCESSWIRE - Tue Nov 18, 8:30AM CST
Golden, CO / ACCESSWIRE / November 19, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of 2014 results and plans for 2015 including advances towards expanded clinical trials of its novel stem cell activation technology.
Vitro Biopharma Launches new Cell Lines to Bolster Revenue Growth
ACCESSWIRE - Tue Oct 28, 8:31AM CDT
Golden, CO / ACCESSWIRE / October 29, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the launch of several new products especially cell lines including stem cells and CAFs-cancer-associated fibroblasts targeting research and clinical development markets in cancer and regenerative medicine. Our new stem cells include neural stem cells (NSCs) derived from MSCs together with an advanced growth media formulation. These cells are suitable for several applications including drug-development, monitoring of stem cell activation procedures and generation of cells for use in cell therapy procedures. Our proprietary enhanced growth medium and NSC expansion methods enable direct use of a patient's olfactory stem cells. Similar methods were used in a procedure recently reported to reverse paralysis in a stabbing victim by microinjection of olfactory bulb-derived cells and nerve engraftment. The olfactory system is known to be a rich source of neural stem cells that have numerous applications in cell therapy including treatment of spinal cord injury.
Efficacy of Stem Cell Therapy for Stroke Demonstrated in Landmark Study using Vitro Biopharma Stem Cells & Media
ACCESSWIRE - Tue Sep 09, 8:37AM CDT
Golden, CO / ACCESSWIRE / September 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the publication of a research study using its stem cells to treat an animal model of stroke. University of Illinois College of Medicine at Peoria (UICOMP) researchers, led by Dr. Krishna Kumar Veeravalli recently published a study showing a prominent reduction in brain damage by treatment of an animal model of ischemic stroke with human MSCs obtained from Vitro Biopharma through its distributor Neuromics, Inc. The study focused on several measures of brain damage by apoptosis, or programmed cell death that resulted from occlusion of the rat carotid artery, an animal stroke model. Death of brain cells leads to paralysis, loss of function, cognitive impairment, and other effects following a stroke. Hence, reversal of cell death can reverse several adverse neurological effects of stroke. Following the intravenous injection of 250,000 or 1,000,000 Vitro Biopharma's human umbilical cord blood-derived MSCs, there was a dramatic and statistically significant reduction of cellular apoptosis compared to untreated groups. The endpoints included DNA damage and expression levels of numerous genes known to be associated with apoptosis. (Neurochem Res 39: 1511-1521, 2014).
Vitro Biopharma Appoints Jeff Liter to its Board of Directors
ACCESSWIRE - Wed Aug 20, 11:15AM CDT
Golden, CO / ACCESSWIRE / August 20, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma is pleased to announce the appointment of Mr. Jeff Liter to its Board of Directors. Mr. Liter is a versatile business executive who has consistently delivered profitable revenue growth across multiple businesses, industries and geographic regions. He presently serves as the Chief Operating Officer of Progenitor Cell Therapy (PCT), a division of NeoStem a stem cell firm traded on the New York Stock Exchange. His impressive accomplishments include leading 10 M & A transactions from $4M to $2.6B in their entirety. It is anticipated that Mr. Liter will accelerate the rapid growth that Vitro Biopharma is now experiencing, especially in enhanced strategic focus, finance, M&A and other growth initiatives as well.
Vitro Biopharma Announces Strong Third Quarter Revenue & Positioning for Further Growth
ACCESSWIRE - Tue Aug 12, 8:32AM CDT
Golden, Colorado / ACCESSWIRE / August 12, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced continued revenue growth in its third fiscal quarter of 2014 and developments to further increase revenue. Total revenues increased over four-fold in the first nine months of 2014 compared to the same period in 2013 from increased product sales and revenues from contract research services.
Frost & Sullivan Honors Vitro Biopharma for its Outstanding Technological Innovations and Business Strategy in the Stem Cell Tools Industry
PR Newswire Europe - Tue Aug 05, 7:46AM CDT
--The company aims to increase the market penetration of its proprietary MSC-based research products, while expanding its stem cell segment to include differentiated cells derived from MSCs
Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America
ACCESSWIRE - Wed Jul 09, 11:00AM CDT
Golden, CO / ACCESSWIRE / July 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies' commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.
Vitro Biopharma Expands Capacity to Meet Increased Demand for MSC-Gro(TM) Stem Cell Culture Media
ACCESSWIRE - Wed Apr 29, 8:26AM CDT
GOLDEN, CO / ACCESSWIRE / April 29, 2015 / Vitro Diagnostics, Inc. (PINKSHEETS: VODG), dba Vitro Biopharma, announced expansion of manufacturing capacity based on a recent orders for bulk quantities of its MSC-Gro(TM) Brand of stem cell growth media. Increased demand comes from sales to stem cell researchers and a new customer who recently qualified our media for use in its clinical testing program. We have received our initial bulk order based on extensive evaluation of Vitro Biopharma's clinical grade MSC-Gro(TM). The evaluation focused on safety/efficacy parameters and showed safety in animal studies and efficacy through MSC authentication including achievement of phenotypic and functional standards following expansion of human adipose-derived MSCs in MSC-Gro(TM). The function of MSC-Gro(TM) in cell expansion was extensively examined and showed that MSC-Gro(TM) produced superior cellular yields than previously utilized products. Vitro Biopharma anticipates regular orders at levels requiring expanded manufacturing capacity since this customer is known to consume large quantities of media.
AMGN: 162.36 (+0.38)
Vitro Biopharma Announces Advances in Clinical Application of Stem Cell Therapy for Neurological Conditions
ACCESSWIRE - Wed Feb 18, 11:43AM CST
GOLDEN, CO / ACCESSWIRE / February 18, 2015 / Vitro Diagnostics, Inc. (OTCQB:VODG), DBA Vitro Biopharma, announced advances in its stem cell products and services that enhance opportunities to expand clinical studies of stem therapy of neurological conditions. We have previously announced a pre-clinical study of our human MSCs for treatment of stroke in animals that showed near reversal of cell death responses to ischemic stroke by carotid artery occlusion. Recently, the renowned hockey legend, Gordy Howe received a stem cell transplant to treat a prior stroke that left him partially paralyzed, unable to speak and losing weight and quality of life quickly. Shortly following stem cell transplantation in two stages, neural stem cells (NSCs) followed by mesenchymal stem cells (MSCs), he began to walk and talk. At present, he is preparing to attend a hockey gala as a keynote speaker. While his progress is considered outstanding by his family and attending physicians, others criticize this study as uncontrolled. We have recently published a blog summarizing clinical and pre-clinical studies that support further, more extensive clinical trials of stem cell therapy of stroke.
Alternatives to Stem Cell Transplants Supported by Key Medical Breakthroughs of 2014
ACCESSWIRE - Tue Jan 13, 9:18AM CST
GOLDEN, CO / ACCESSWIRE / January 13, 2015 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the growing scientific support for use of stem cells that reside within the body for therapeutic and performance enhancement. A key medical advance of 2014 was research published by scientists at Stanford University and Harvard University regarding mechanisms underlying "parabiosis", the well-known reversal of aging when young animal blood is transferred into older animals. This research, considered a key scientific advance of 2014, identified factors in blood that transform stem cells from an inactive, latent form to active cells that regenerate and replenish aging cells resulting in reversal of aging in animals. This newly identified factor, called growth-differentiation factor 11 (GDF11, or, BMP-11) adds to a growing list of endogenous biological agents that activate stem cells from quiescence to growth and differentiation. The well-known growth factors erythropoietin and G-CSF have been used as therapeutic agents for 25 years to treat anemia and immuno-suppression resulting from chemotherapy. Many stem cells exist within the body in a latent, inactive form ready to be activated by the proper molecular "switch".
Vitro Biopharma Announces CEO Letter to Shareholders: 2014 Revenue Growth Supports 2015 Expansion of Stem Cell Clinical Trials & Revenue
ACCESSWIRE - Tue Nov 18, 8:30AM CST
Golden, CO / ACCESSWIRE / November 19, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of 2014 results and plans for 2015 including advances towards expanded clinical trials of its novel stem cell activation technology.
Vitro Biopharma Launches new Cell Lines to Bolster Revenue Growth
ACCESSWIRE - Tue Oct 28, 8:31AM CDT
Golden, CO / ACCESSWIRE / October 29, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the launch of several new products especially cell lines including stem cells and CAFs-cancer-associated fibroblasts targeting research and clinical development markets in cancer and regenerative medicine. Our new stem cells include neural stem cells (NSCs) derived from MSCs together with an advanced growth media formulation. These cells are suitable for several applications including drug-development, monitoring of stem cell activation procedures and generation of cells for use in cell therapy procedures. Our proprietary enhanced growth medium and NSC expansion methods enable direct use of a patient's olfactory stem cells. Similar methods were used in a procedure recently reported to reverse paralysis in a stabbing victim by microinjection of olfactory bulb-derived cells and nerve engraftment. The olfactory system is known to be a rich source of neural stem cells that have numerous applications in cell therapy including treatment of spinal cord injury.
Efficacy of Stem Cell Therapy for Stroke Demonstrated in Landmark Study using Vitro Biopharma Stem Cells & Media
ACCESSWIRE - Tue Sep 09, 8:37AM CDT
Golden, CO / ACCESSWIRE / September 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the publication of a research study using its stem cells to treat an animal model of stroke. University of Illinois College of Medicine at Peoria (UICOMP) researchers, led by Dr. Krishna Kumar Veeravalli recently published a study showing a prominent reduction in brain damage by treatment of an animal model of ischemic stroke with human MSCs obtained from Vitro Biopharma through its distributor Neuromics, Inc. The study focused on several measures of brain damage by apoptosis, or programmed cell death that resulted from occlusion of the rat carotid artery, an animal stroke model. Death of brain cells leads to paralysis, loss of function, cognitive impairment, and other effects following a stroke. Hence, reversal of cell death can reverse several adverse neurological effects of stroke. Following the intravenous injection of 250,000 or 1,000,000 Vitro Biopharma's human umbilical cord blood-derived MSCs, there was a dramatic and statistically significant reduction of cellular apoptosis compared to untreated groups. The endpoints included DNA damage and expression levels of numerous genes known to be associated with apoptosis. (Neurochem Res 39: 1511-1521, 2014).
Vitro Biopharma Appoints Jeff Liter to its Board of Directors
ACCESSWIRE - Wed Aug 20, 11:15AM CDT
Golden, CO / ACCESSWIRE / August 20, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma is pleased to announce the appointment of Mr. Jeff Liter to its Board of Directors. Mr. Liter is a versatile business executive who has consistently delivered profitable revenue growth across multiple businesses, industries and geographic regions. He presently serves as the Chief Operating Officer of Progenitor Cell Therapy (PCT), a division of NeoStem a stem cell firm traded on the New York Stock Exchange. His impressive accomplishments include leading 10 M & A transactions from $4M to $2.6B in their entirety. It is anticipated that Mr. Liter will accelerate the rapid growth that Vitro Biopharma is now experiencing, especially in enhanced strategic focus, finance, M&A and other growth initiatives as well.
Vitro Biopharma Announces Strong Third Quarter Revenue & Positioning for Further Growth
ACCESSWIRE - Tue Aug 12, 8:32AM CDT
Golden, Colorado / ACCESSWIRE / August 12, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced continued revenue growth in its third fiscal quarter of 2014 and developments to further increase revenue. Total revenues increased over four-fold in the first nine months of 2014 compared to the same period in 2013 from increased product sales and revenues from contract research services.
Frost & Sullivan Honors Vitro Biopharma for its Outstanding Technological Innovations and Business Strategy in the Stem Cell Tools Industry
PR Newswire Europe - Tue Aug 05, 7:46AM CDT
--The company aims to increase the market penetration of its proprietary MSC-based research products, while expanding its stem cell segment to include differentiated cells derived from MSCs
Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America
ACCESSWIRE - Wed Jul 09, 11:00AM CDT
Golden, CO / ACCESSWIRE / July 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies' commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.
